Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Exclusively Distribute DiscoveRx s HitHunter cAMP Assays Worldwide

NEW YORK, May 24 (GenomeWeb News) - GE Healthcare signed an exclusive distribution agreement with DiscoveRx for its HitHunter cAMP assays, GE Healthcare said today.

Terms of the deal call for GE to exclusivelty distribute DiscoveRx's HitHunter cAMP Enzyme Fragment Complementation-based assays worldwid. The deal also expands GE's rights to distribute DiscoveRx's portfolio of kinase assays, with exclusive distribution in the Asia-Pacific region.

 

The cAMP assays are designed for high throughput, non-radioactive screening of compounds in drug discovery. The homogeneous cell-based assays are used to screen for G-protein coupled receptor activation in a microplate-based format.
 

Financial details were not disclosed.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.